Results 121 to 130 of about 577 (167)
Cardiovascular Risks in People With Narcolepsy: Expert Panel Consensus Recommendations. [PDF]
J Am Heart AssocKwon Y +6 more
europepmc +1 more source
A Survey of People Living with Narcolepsy in the USA: Path to Diagnosis, Quality of Life, and Treatment Landscape from the Patient's Perspective. [PDF]
CNS DrugsOrtiz LE +7 more
europepmc +1 more source
The translational potential of sleep and circadian rhythm disturbances as a biomarker of Alzheimer's disease [PDF]
, 2018 Feldman, HH +8 more
core +1 more source
Narcolepsy: Beyond the Classic Pentad. [PDF]
CNS DrugsMorse AM, Kim SY, Harris S, Gow M.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
SLEEP
Abstract Introduction A novel once-nightly formulation of sodium oxybate (ON-SXB; LUMRYZ™) was investigated in patients with narcolepsy type 1 (NT1) and 2 (NT2) in the phase 3 REST-ON trial (NCT02720744).
Luis Ortiz +7 more
semanticscholar +4 more sources
Abstract Introduction A novel once-nightly formulation of sodium oxybate (ON-SXB; LUMRYZ™) was investigated in patients with narcolepsy type 1 (NT1) and 2 (NT2) in the phase 3 REST-ON trial (NCT02720744).
Luis Ortiz +7 more
semanticscholar +4 more sources
Sleep Medicine, 2022
OBJECTIVES Treatment for narcolepsy with sodium oxybate (SXB) has required twice-nightly dosing, at bedtime and 2.5-4 h later. This study evaluated the pharmacokinetics of FT218, an investigational, extended-release, once-nightly formulation of SXB (ON ...
R. Bogan +5 more
semanticscholar +3 more sources
OBJECTIVES Treatment for narcolepsy with sodium oxybate (SXB) has required twice-nightly dosing, at bedtime and 2.5-4 h later. This study evaluated the pharmacokinetics of FT218, an investigational, extended-release, once-nightly formulation of SXB (ON ...
R. Bogan +5 more
semanticscholar +3 more sources
0638 Stability of Once-Nightly Sodium Oxybate in Alternative Liquid Reconstitution Vehicles
SLEEPAbstract Introduction LUMRYZ™ is a once-nightly formulation of sodium oxybate (ON-SXB) containing both immediate and pH-dependent controlled-release granules designed to be reconstituted in water and administered orally.
Maggie Lavender +6 more
openaire +2 more sources
SLEEP
Abstract Introduction Extended-release, once-nightly sodium oxybate (ON-SXB; LUMRYZ™) eliminates the middle-of-the-night dosing required with immediate-release, twice-nightly oxybates (TN-OXBs). RESTORE (NCT04451668) was an open label/switch study that assessed the safety and tolerability of ON-SXB in
Adrian Santamaria +7 more
openaire +2 more sources
Abstract Introduction Extended-release, once-nightly sodium oxybate (ON-SXB; LUMRYZ™) eliminates the middle-of-the-night dosing required with immediate-release, twice-nightly oxybates (TN-OXBs). RESTORE (NCT04451668) was an open label/switch study that assessed the safety and tolerability of ON-SXB in
Adrian Santamaria +7 more
openaire +2 more sources
SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) was investigated in patients with narcolepsy type 1 (NT1) or 2 (NT2) in the phase 3 REST-ON trial; treatment with 6, 7.5, and 9 g demonstrated significant improvements vs placebo (all P< 0.001) for the coprimary endpoints of ...
Michael Thorpy +7 more
openaire +2 more sources
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) was investigated in patients with narcolepsy type 1 (NT1) or 2 (NT2) in the phase 3 REST-ON trial; treatment with 6, 7.5, and 9 g demonstrated significant improvements vs placebo (all P< 0.001) for the coprimary endpoints of ...
Michael Thorpy +7 more
openaire +2 more sources
SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is approved to treat excessive daytime sleepiness and cataplexy in adult and pediatric patients ≥7 years of age with narcolepsy. The REFRESH study assesses the clinical effectiveness, patient satisfaction, and safety of ON-SXB for the
Sarah Meskill +9 more
openaire +2 more sources
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is approved to treat excessive daytime sleepiness and cataplexy in adult and pediatric patients ≥7 years of age with narcolepsy. The REFRESH study assesses the clinical effectiveness, patient satisfaction, and safety of ON-SXB for the
Sarah Meskill +9 more
openaire +2 more sources